Long-term prophylaxis in von Willebrand disease

Area of Science:

• Hematology
• Bleeding Disorders
• Internal Medicine

Background:

• Von Willebrand disease (VWD) often presents with mild mucosal bleeding, but severe bleeding and joint impairment can occur.
• Prophylactic treatment is established for severe hemophilia and warrants evaluation in VWD patients with recurrent bleeding.
• Limited data exists on the long-term efficacy and safety of prophylaxis in various VWD subtypes.

Purpose of the Study:

• To evaluate the effectiveness and safety of long-term prophylactic treatment in patients with von Willebrand disease (VWD).
• To assess the impact of early-onset prophylaxis on preventing joint bleeds and arthropathy in VWD.
• To determine the suitability of prophylaxis for different VWD subtypes with severe bleeding tendencies.

Main Methods:

• Retrospective analysis of 35 patients with VWD types 3, 2A, 2B, and 1 receiving long-term prophylaxis.
• Data collected from Malmo University Hospital and Karolinska University Hospital, Stockholm.
• Evaluation of bleeding episode frequency, joint bleeds, arthropathy development, and treatment safety (thrombosis, viral transmission).

Main Results:

• Long-term prophylaxis led to a substantial reduction in bleeding episodes across VWD subtypes.
• Patients initiating prophylaxis before age 5 experienced no joint bleeds or signs of arthropathy.
• Treatment was safe, with no reported cases of thrombosis or viral transmission with the specific concentrate used.

Conclusions:

• Long-term prophylaxis is indicated for most patients with type 3 VWD and other severe bleeding VWD subtypes.
• Early prophylaxis initiation can prevent joint disease in VWD patients.
• Further clinical data and controlled trials are necessary to establish formal prophylaxis recommendations for VWD.